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Introduction
Chronic inflammatory demyelinating polyradiculoneuropa-
thy (CIDP) is a progressive or relapsing and remitting dis-
ease of the peripheral nervous system. It is generally thought 
to have an autoimmune aetiology and has a global preva-
lence estimated at 0.8–8.9 per 100,000. In its classical form, 
it is characterised by a symmetric proximal and distal weak-
ness and sensory dysfunction of all extremities, developing 
over at least 2 months. Less commonly, CIDP may present 
with cranial nerve involvement, pure motor, pure sensory, 
asymmetric or predominately distal limb dysfunction.
The optimum treatment for CIDP has long been an area of 
debate, although with a consensus for the use of intravenous 
immunoglobulin (IVIg) as an induction and maintenance 
treatment. Trials have demonstrated that IVIg is effective 
in the short- and long-term treatment and well tolerated. 
However, there are considerable cost implications for the 
long-term use of IVIg, as well as the infrastructure required 
to administer an infusion for 2–3 days at intervals that may 
be as short as every 3–6 weeks. Corticosteroids, although 
known since 1958 to be an effective treatment choice in 
CIDP with response rates reported between 30 and 90%, 
have well-recognised cumulative side effects. However, 
alternative immunosuppressants such as azathioprine, meth-
otrexate or rituximab are commonly viewed as alternatives 
to IVIg particularly in healthcare systems that may be unable 
to provide invasive treatments such as plasma exchange or 
IVIg. As a result, research has focussed on identifying alter-
native immunomodulating agents that are more convenient, 
cost effective and improve patient outcomes and autonomy.
This month’s journal club will review three treatment 
options in the management of CIDP. The first paper reviews 
the use of subcutaneous immunoglobulin (SCIg) in the 
PATH trial; the second looks at the use of different regimes 
of corticosteroids and the last reviews the novel use of fin-
golimod in the FORCIDP trial.
Subcutaneous immunoglobulin 
for maintenance treatment in chronic 
inflammatory demyelinating 
polyneuropathy (PATH)
This international, randomised, double-blind, placebo-con-
trolled, phase 3 trial reviewed the use of two different doses 
of SCIg in CIDP. SCIg has been already been used for many 
years in conditions such as primary immunodeficiency, with 
proven efficacy and is often preferred by patients. In this 
study, 172 patients received either SCIG at a dose of 0.4 g/
kg (high dose), 0.2 g/kg (low dose) or placebo. Following 
screening, dependency on IVIg was assessed by withhold-
ing current IVIg treatment for 12 weeks and monitoring 
response. Those deemed dependent were then put through an 
IVIg re-stabilisation period to acquire a standardised regime. 
Patients were assessed using the Inflammatory Neuropathy 
Cause and Treatment (INCAT) scoring system at the end 
of the re-stabilisation period, which acted as baseline for 
future assessments. Those successfully re-stabilised were 
then entered into a 24-week treatment period.
Primary outcome measure was the proportion of patients 
who had a relapse or were withdrawn from the study for 
any reason during the treatment period. The absolute risk 
reduction for the primary outcome was 25% in the low-dose 
group and 30% in the high-dose group compared with pla-
cebo. The probability of remaining relapse free by the end 
of the treatment period was estimated to 77.6% in the high-
dose group, 65.0% in the low-dose group and 41.2% in the 
placebo group. The number needed to treat (NNT) to prevent 
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one relapse of CIDP was 2.7 in the high-dose group and 4.4 
in the low-dose group. SCIg was well tolerated by patients, 
with adverse event rates equal across all three groups with 
the majority for minor skin reactions. Patients also reported 
a preference for the use of SCIg, as it improved autonomy 
and had fewer side effects.
Comment This well-designed study demonstrates com-
parable NNT (2.7, 4.4) to IVIg in CIDP as calculated in 
a Cochrane review (3.03). It also highlights some posi-
tive patient outcomes for a treatment that can be lifelong. 
Limitations of the study included patient numbers despite 
the involvement of 69 neuromuscular centres. In addition, 
although attempts were made to ensure patients were IVIg 
dependent, 44% of patients in the placebo group did not 
relapse. Whilst this phenomenon is common in CIDP tri-
als, it does demonstrate some of the practical difficulties of 
identifying appropriate cohorts despite wide engagement by 
relevant centres.
van Schaik et  al. (2018) The Lancet Neurology; 17: 
35–46.
Corticosteroids in chronic inflammatory 
demyelinating polyneuropathy
There is currently no consensus for the use of a common 
corticosteroid regime in CIDP. In this multinational retro-
spective analysis, treatment naïve CIDP patients prescribed a 
defined regime of oral prednisolone, pulsed oral dexametha-
sone or intravenous methylprednisolone were reviewed.
Patients who met the European Federation of Neurologi-
cal Societies/Peripheral Nerve Society diagnostic criteria for 
(EFNS/PNS) for definite, probable, or possible CIDP were 
included. Those deemed to have severe, ‘fast progressive’ or 
a pure motor phenotype CIDP were excluded. Disease sever-
ity at baseline was assessed by the medical research councils 
(MRC) sum score and a modified Rankin scale score (mRS). 
Primary outcome was the number of responders in each arm, 
defined as any patient who showed improvement in motor 
or sensory impairment as captured by the treating neurolo-
gist and/or the mRS, and did not require additional treat-
ment for CIDP. Primary outcome was assessed at 6 months 
from treatment onset. Secondary outcomes included, time 
to relapse, adverse events and 5-year remission rate as meas-
ured on the CIDP disease activity status score (CDAS).
In total, 125 patients were recruited, 58 from Serbia 
with 98% of these taking the defined prednisolone regime. 
From the Netherlands, 43 patients were recruited with 86% 
taking the dexamethasone regime. Finally, 24 patients 
were recruited from Italy with 83% taking the methylpred-
nisolone regime. Overall, 75 (60%) of patients met the 
primary outcome measures and were considered respond-
ers. There was no statistical significance between the three 
groups for the primary outcome. Of the 75 responders, 46 
(61%) remained remission free during a median follow-up 
of 55 months (1–197) and 55% of the patients achieved a 
5-year remission. For all 125 patients, the 5-year remission 
rate was 33%.
Comment This study explored three corticosteroid 
regimes, with a long follow-up period. Limitations include 
uneven distribution of patients between the regimes (54% 
of patients were in the prednisolone arm of the study) and 
the potential for inter-observer bias. Although there was 
no statistical significance between the three groups, pulsed 
dexamethasone provided the smallest cumulative dose of 
corticosteroid and 91% of patients responded to either 
corticosteroids alone, or corticosteroids followed by IVIg.
van Lieverloo et al. (2018) Journal of Neurology; 265: 
2052–2059.
Oral fingolimod for chronic inflammatory 
demyelinating polyneuropathy (FORCIDP 
trial): a double‑blind, multicenter, 
randomised control trial
Fingolimod is a sphingosine 1-phosphate receptor modula-
tor with a well-established role in the treatment of relaps-
ing multiple sclerosis and causes retention of autoreac-
tive T cells in lymph nodes with subsequent reduction in 
circulating naïve T and B cells. In this study by Hughes 
et al., patients previously on either IVIg or corticoster-
oids for CIDP were recruited from 14 countries and given 
fingolimod or placebo in a double-blind randomised trial. 
Patients were required to meet the EFNS/PNS defini-
tion for CIDP, have an INCAT score at screening of 1–9 
and have a documented clinical deterioration in the last 
18 months but should have been clinically stable in the 
6 weeks prior to randomisation. Primary outcome was 
time to first confirmed worsening, defined by an increase 
in the INCAT score of at least one. An interim analysis 
was planned after 50 observed events.
One hundred and six patients were recruited and ran-
domised. The study was ended at 3 years when the interim 
analysis concluded that there was no difference between 
the two groups for any of the study outcomes. Confirmed 
worsening was seen in 42% of the fingolimod group and 
43% of the placebo group, with a hazard ratio of 1.0 cal-
culated for the use of fingolimod.
Comment This study found no evidence for benefit of 
fingolimod in CIDP. The authors did note that the relapse-
free rate in the placebo group was 42% indicating that 
patients with inactive CIDP were included in the study. 
Although some attempts were made to exclude patients 
with inactive disease, using a similar screening step to 
that used in PATH trial could have been more beneficial. 
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In addition, patients on IVIg started treatment the day after 
last dose, whereas those on corticosteroids started on ini-
tiation of their dose tapering. This resulted in patients on 
corticosteroids having a more gentle transition to the study 
drug than those on IVIg. Fingolimod is estimated to take 
2–6 weeks to achieve full activity and therefore this may 
have resulted in patients relapsing before it had reached 
maximal efficacy.
Hughes et al. (2018) The Lancet Neurology; 17: 689–698.
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